Literature DB >> 17608768

Flow cytometric detection of circulating tumour cells in nucleophosmin/anaplastic lymphoma kinase-positive anaplastic large cell lymphoma: comparison with quantitative polymerase chain reaction.

Christine Damm-Welk1, Jutta Schieferstein, Simone Schwalm, Alfred Reiter, Willi Woessmann.   

Abstract

Quantification of occult circulating tumour cells in blood or bone marrow (BM) enables the identification of patients with a high risk for relapse in nucleophosmin/anaplastic lymphoma kinase (NPM-ALK)-positive anaplastic large cell lymphoma (ALCL). We have developed a flow cytometric (FCM) assay to quantify the rare ALK- and CD30-positive ALCL cells. When ALCL cells were admixed with normal peripheral blood or BM, ALK- and CD30-positive cells could be detected above background level at an added concentration of 10(-5) for all three cell lines tested. Sensitivity and costs of the assay were compared with quantitative real-time polymerase chain reaction (PCR) for NPM-ALK. The results of the FCM assay and quantitative PCR for NPM-ALK correlated. The sensitivity of the PCR exceeded that of the FCM by at least one log. Quantitative PCR was more time-consuming and expensive than FCM. Both methods were compared on BM or blood samples from 11 ALCL patients. FCM using antibodies against ALK and CD30 can sensitively and specifically detect the circulating ALCL cells in BM or blood. This method needs to be tested in a larger cohort of patients to determine whether it has sufficient sensitivity to be used as a substitute for quantitative PCR.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17608768     DOI: 10.1111/j.1365-2141.2007.06672.x

Source DB:  PubMed          Journal:  Br J Haematol        ISSN: 0007-1048            Impact factor:   6.998


  8 in total

Review 1.  Non-Hodgkin Lymphoma in Children.

Authors:  John T Sandlund
Journal:  Curr Hematol Malig Rep       Date:  2015-09       Impact factor: 3.952

2.  Revised International Pediatric Non-Hodgkin Lymphoma Staging System.

Authors:  Angelo Rosolen; Sherrie L Perkins; C Ross Pinkerton; R Paul Guillerman; John T Sandlund; Catherine Patte; Alfred Reiter; Mitchell S Cairo
Journal:  J Clin Oncol       Date:  2015-05-04       Impact factor: 44.544

3.  International Pediatric Non-Hodgkin Lymphoma Response Criteria.

Authors:  John T Sandlund; R Paul Guillerman; Sherrie L Perkins; C Ross Pinkerton; Angelo Rosolen; Catherine Patte; Alfred Reiter; Mitchell S Cairo
Journal:  J Clin Oncol       Date:  2015-05-04       Impact factor: 44.544

4.  Minimal disseminated disease in childhood T-cell lymphoblastic lymphoma: a report from the children's oncology group.

Authors:  Elaine Coustan-Smith; John T Sandlund; Sherrie L Perkins; Helen Chen; Myron Chang; Minnie Abromowitch; Dario Campana
Journal:  J Clin Oncol       Date:  2009-06-22       Impact factor: 44.544

5.  Isolation of rare cells from cell mixtures by dielectrophoresis.

Authors:  Peter R C Gascoyne; Jamileh Noshari; Thomas J Anderson; Frederick F Becker
Journal:  Electrophoresis       Date:  2009-04       Impact factor: 3.535

6.  Immunophenotypic shifts during minimal residual evaluation in a case of leukemic form of anaplastic large cell lymphoma ALK.

Authors:  Maria Clara Canellas; Enrico Bruno-Riscarolli; Cristiane S Ferreira-Facio; Daiana V Lopes-Alves; Vitor D Botafogo; Deborah Sutter; Roberia M Pontes; Marcelo G P Land; Cristiane Bedran Milito; Elaine Sobral da Costa
Journal:  Cancer Rep (Hoboken)       Date:  2021-08-11

7.  Simultaneous cytomorphological and multiparameter flow cytometric analysis of ALK-positive anaplastic large cell lymphoma in children.

Authors:  Hongqiang Shen; Yongmin Tang; Xiaojun Xu; Hongfeng Tang; Weizhong Gu
Journal:  Oncol Lett       Date:  2012-11-19       Impact factor: 2.967

8.  Recombinant expression, characterization, and quantification in human cancer cell lines of the Anaplastic Large-Cell Lymphoma-characteristic NPM-ALK fusion protein.

Authors:  Katerina Kourentzi; Mary Crum; Ujwal Patil; Ana Prebisch; Dimple Chavan; Binh Vu; Zihua Zeng; Dmitri Litvinov; Youli Zu; Richard C Willson
Journal:  Sci Rep       Date:  2020-03-19       Impact factor: 4.379

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.